Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001206319 | SCV001377621 | pathogenic | Arthrogryposis, distal, type 1A | 2024-01-05 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 41 of the TPM2 protein (p.Glu41Lys). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with clinical features of autosomal dominant TPM2-related conditions (PMID: 17846275, 24692096). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 12464). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt TPM2 protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects TPM2 function (PMID: 18420702, 22084935, 24039757, 25978979). For these reasons, this variant has been classified as Pathogenic. |
OMIM | RCV000013280 | SCV000033527 | pathogenic | Congenital myopathy 23 | 2007-09-01 | no assertion criteria provided | literature only | |
TPM2 homepage - |
RCV000128672 | SCV000172312 | not provided | not provided | no assertion provided | not provided |